Biochemical studies on the potentiation of antitumor activity of cisplatin by adriamycin

Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis

“…The failure of postoperative intraperitoneal drug administration may be correlated with heterogeneous drug distribution caused by early postoperative adhesions entrapping tumor cells and protecting them from the chemotherapeutic agents 23. In addition, some antineoplastic drugs (e.g., doxorubicin and cisplatin) act synergistically with each other24, 25 and with heat,26, 27 which led some authors to propose hyperthermic intraperitoneal intraoperative chemotherapy (HIIC) for the treatment of locally advanced intraabdominal malignancies 17, 28. The results of cytoreductive surgery combined with HIIC for the treatment of gastrointestinal carcinomas have been encouraging 18, 29–38.…”

“…As a single drug regimen, it has been administered intraperitoneally in patients with advanced ovarian carcinoma, but patients develop high local toxicity 40. Some studies demonstrated in preclinical models that doxorubicin activity is enhanced by the addition of cisplatin24, 25 and/or hyperthermia 26, 27, 41. This potential synergy might be exploited to reduce the doxorubicin dosage (and thus minimize doxorubicin‐related local toxicity) while still maintaining the therapeutic activity of the cytotoxic regimen.…”